If you trade catalysts, map the dates and ignore the noise. For MYNZ, I set three near term anchors. First, AACR 2026 in San Diego, where the pancreatic verification read uses a compact blood mRNA panel with an AI model to detect PDAC and sort IPMN. Prior feasibility printed 100 percent sensitivity and 95 percent specificity in 30 subjects; the question is whether the trimmed panel holds up. Second, eAArly DETECT 2 feasibility for CRC is guided to wrap in H1 2026, which sets up the 2026 pivotal. Third, Europe is the operating bridge now that the UK and Switzerland are open and DoctorBox in Germany can funnel real orders.
Execution triggers to watch:
* Abstract posting and poster day at AACR, then sensitivity, specificity, AUC, and stage mix
* Feasibility enrollment cadence and any multicenter QC
* Weekly EU conversions, completed kits, turnaround, and reorders by country
Low float means velocity both ways. Size around levels and news.
Not Advice.